frovatriptan ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
serotonin (5-HT1) receptor agonists, sumatriptan derivatives 1251 158747-02-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • frovatriptan
  • (R)-Frovatriptan
  • frovatriptan succinate
  • frovatriptan succinate hydrate
  • SB 209509
  • VML251
  • Molecular weight: 243.31
  • Formula: C14H17N3O
  • CLOGP: 0.72
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 3
  • TPSA: 70.91
  • ALOGS: -3.30
  • ROTB: 2

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
2.50 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 6 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.44 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 27 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 3.60 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 2.50 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.85 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 24 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Nov. 8, 2001 FDA ENDO PHARMS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Neovascularisation 154.32 29.56 27 1623 986 50602488
Migraine 135.26 29.56 60 1590 75220 50528254
Paradoxical drug reaction 119.82 29.56 27 1623 3620 50599854
Anuria 89.66 29.56 27 1623 11217 50592257
Extrapyramidal disorder 88.45 29.56 27 1623 11743 50591731
Drug ineffective for unapproved indication 80.19 29.56 29 1621 21252 50582222
Lichen planus 50.82 29.56 12 1638 1967 50601507
Dyspepsia 48.22 29.56 30 1620 74067 50529407
Cough 33.23 29.56 40 1610 241224 50362250
Weight decreased 32.65 29.56 38 1612 221207 50382267

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Neovascularisation 160.41 43.49 27 1515 1076 64496114
Migraine 124.12 43.49 49 1493 62628 64434562
Paradoxical drug reaction 114.26 43.49 27 1515 6093 64491097
Anuria 84.03 43.49 27 1515 18937 64478253
Extrapyramidal disorder 83.22 43.49 27 1515 19525 64477665
Drug ineffective for unapproved indication 74.56 43.49 28 1514 31105 64466085
Dyspepsia 60.24 43.49 32 1510 80280 64416910

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N02CC07 NERVOUS SYSTEM
ANALGESICS
ANTIMIGRAINE PREPARATIONS
Selective serotonin (5HT1) agonists
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018490 Serotonin Agents
MeSH PA D017366 Serotonin Receptor Agonists
FDA MoA N0000175763 Serotonin 1b Receptor Agonists
FDA MoA N0000175764 Serotonin 1d Receptor Agonists
FDA EPC N0000175765 Serotonin-1b and Serotonin-1d Receptor Agonist

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Migraine indication 37796009 DOID:6364
Hypercholesterolemia contraindication 13644009
Coronary artery spasm contraindication 23687008 DOID:11840
Hypertensive disorder contraindication 38341003 DOID:10763
Conduction disorder of the heart contraindication 44808001
Hemiplegic migraine contraindication 59292006
Diabetes mellitus contraindication 73211009 DOID:9351
Vascular insufficiency of intestine contraindication 82196007
Prinzmetal angina contraindication 87343002
Angina pectoris contraindication 194828000
Cerebrovascular accident contraindication 230690007
Transient ischemic attack contraindication 266257000 DOID:224
Raynaud's phenomenon contraindication 266261006
Serotonin syndrome contraindication 371089000
Cardiovascular event risk contraindication 395112001
Peripheral vascular disease contraindication 400047006
Disorder of coronary artery contraindication 414024009
Myocardial ischemia contraindication 414795007 DOID:3393
Obesity contraindication 414916001 DOID:9970
Hypertensive urgency contraindication 443482000




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 12.14 acidic
pKa2 12.79 acidic
pKa3 10.16 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
5-hydroxytryptamine receptor 1B GPCR AGONIST Ki 7.99 CHEMBL CHEMBL
5-hydroxytryptamine receptor 1D GPCR AGONIST Ki 8.36 CHEMBL CHEMBL
5-hydroxytryptamine receptor 1A GPCR Ki 7.21 CHEMBL

External reference:

IDSource
4021297 VUID
N0000148734 NUI
D04264 KEGG_DRUG
158930-17-7 SECONDARY_CAS_RN
4021297 VANDF
C0754647 UMLSCUI
CHEBI:134991 CHEBI
CHEMBL1279 ChEMBL_ID
DB00998 DRUGBANK_ID
CHEMBL2138684 ChEMBL_ID
CHEMBL1200371 ChEMBL_ID
C108128 MESH_SUPPLEMENTAL_RECORD_UI
77992 PUBCHEM_CID
7191 IUPHAR_LIGAND_ID
7661 INN_ID
H82Q2D5WA7 UNII
228783 RXNORM
16207 MMSL
239641 MMSL
d04776 MMSL
009509 NDDF
009510 NDDF
370214004 SNOMEDCT_US
411990007 SNOMEDCT_US
767324002 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Frovatriptan HUMAN PRESCRIPTION DRUG LABEL 1 0378-3140 TABLET, FILM COATED 2.50 mg ORAL ANDA 26 sections
Frovatriptan Succinate HUMAN PRESCRIPTION DRUG LABEL 1 0603-3718 TABLET, FILM COATED 2.50 mg ORAL NDA 25 sections
FROVA HUMAN PRESCRIPTION DRUG LABEL 1 16590-396 TABLET, FILM COATED 2.50 mg ORAL NDA 25 sections
FROVA HUMAN PRESCRIPTION DRUG LABEL 1 63481-025 TABLET, FILM COATED 2.50 mg ORAL NDA 25 sections
frovatriptan succinate HUMAN PRESCRIPTION DRUG LABEL 1 68462-694 TABLET, FILM COATED 2.50 mg ORAL ANDA 25 sections
Frovatriptan HUMAN PRESCRIPTION DRUG LABEL 1 69238-1539 TABLET, FILM COATED 2.50 mg ORAL ANDA 25 sections